Abstract P6-11-01: Intermittent High Dose Proton Pump Inhibitor Improves Progression Free Survival As Compared to Standard Chemotherapy in the First Line Treatment of Patients with Metastatic Breast Cancer
X. Hu,B. Wang,S. Sun,A. Chiesi,J. Wang,J. Zhang,S. Fais
DOI: https://doi.org/10.1158/0008-5472.sabcs12-p6-11-01
IF: 11.2
2012-01-01
Cancer Research
Abstract:Abstract Purpose: High dose proton pump inhibitor (PPI) has proved to be potentially effective when combined with chemotherapy in preclinical data. This study (NCT01069081) was designed to investigate whether the efficacy of chemotherapy could be improved with the addition of proton pump inhibitor (PPI) in patients with metastatic breast cancer. Patients and Methods: Females elder than 18 years old with histologically confirmed metastatic breast cancer were eligible for participation. Patients enrolled were randomly assigned to three arms: Arm A, docetaxol 75 mg/m2 on d4, followed by cisplatin 75 mg/m2 on d4, repeated every 21 days until maxinum 6 cycles or presence of disease progression or intolerable toxicity; Arm B, the same chemotherapy plus esomeprazole 80 mg p.o. bid three days on and the subsequent four days off, beginning on d1 repeated weekly up to disease progression, intolerable toxicity, patient's withdrawal, or a maximum of 66 weeks; Arm C, the same as Arm B with the only difference being dose of esomeprazole at 100 mg p.o. bid. The primary endpoint was progression free survival (PFS), and the secondary endpoints were time to progression (TTP), objective response rate (ORR), safety profile, and overall survival (OS). Results: From Aug. 2009 to Dec. 2011, 100 women signed informed consent form (ICF) and 94 patients have undergone at least one injection of chemotherapy. Three patients had severe hypersensitivity reactions, two occurring after the first injection of docetaxol and one in the second cycle. After a median follow up of 17 months, 68 (72.3%) patients got disease progression and 23 (24.5%) patients died. Median PFS for the whole group (n = 94), arm A (n = 33), arm B (n = 30), arm C (n = 31) were 8.9, 7.5, 10.9, and 9.5 months, respectively (p = 0.082). A significant difference was observed between patients who had taken PPI and who not with median PFS of 9.5 and 7.5 months, respectively (p = 0.030). Among 17 patients with triple negative breast cancer, this difference was bigger with median PFS of 9.5 and 3.3 months, respectively (p = 0.014). The overall response rates for the whole group, arm A, arm B, arm C were 58.5%, 51.5%, 63.3%, 61.3%, respectively. Conclusion: This trial is the first randomized study to demonstrate antitumor effects of intermittent high dose PPI in patients with metastatic breast cancer. Docetaxel and cisplatin doublet is comparable to the other first-line chemotherapeutical regimens and the addition of proton pump inhibitor to the doublet improves efficacy with no adding toxicity, especially in patients with triple negative breast cancer. Key Words Proton Pump Inhibitor (PPI), Triple Negative Breast Cancer (TNBC), Phase II Study, Metastatic Breast Cancer, Chemotherapy Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-11-01.